| Literature DB >> 31671144 |
Joon-Myoung Kwon1,2, Ki-Hyun Jeon2,3, Hyue Mee Kim3, Min Jeong Kim3, Sungmin Lim3, Kyung-Hee Kim2,3, Pil Sang Song3, Jinsik Park3, Rak Kyeong Choi3, Byung-Hee Oh3.
Abstract
OBJECTIVE: Conventional risk stratification models for mortality of acute myocardial infarction (AMI) have potential limitations. This study aimed to develop and validate deep-learning-based risk stratification for the mortality of patients with AMI (DAMI).Entities:
Mesh:
Year: 2019 PMID: 31671144 PMCID: PMC6822714 DOI: 10.1371/journal.pone.0224502
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow chart.
Fig 2Deep-learning based model development and accuracy test.
AMI denotes acute myocardial infarction, CKMB creatinine kinase-MB, CVA cerebrovascular accident, DM diabetes mellitus, HTN hypertension, PMHx past medical history, ReLU rectified linear unit.
Fig 3Receiver operating characteristic curve for predicting in-hospital mortality.
AUC denotes area under the receiver operating characteristic curve, CI confidence interval, GRACE global registry of acute coronary event, TIMI thrombolysis in myocardial infarction.
Baseline characteristics of study subjects.
| Derivation data | Validation data | ||||
|---|---|---|---|---|---|
| All population | Low risk group | Intermediate risk group | High risk group | ||
| Age, year | 64.0 ± 12.8 | 63.63 ± 12.6 | 56.1 ± 10.7 | 68.3 ± 9.6 | 71.9 ± 10.8 |
| Female (%) | 3521(29.0%) | 2992(27.9%) | 778(15.8%) | 1033(34.9%) | 1181(41.5%) |
| Body mass index, kg/m2 | 24.0 ± 3.6 | 24.0 ± 3.3 | 24.9 ± 3.6 | 23.4 ± 2.7 | 23.1 ± 3.1 |
| Hypertension (%) | 6218(51.2%) | 5173(48.2%) | 1947(39.5%) | 1541(52.1%) | 1685(59.3%) |
| Diabetes (%) | 3432(28.2%) | 2885(26.9%) | 866(17.6%) | 891(30.1%) | 1128(39.7%) |
| Dyslipidemia (%) | 1553(12.8%) | 1163(10.8%) | 642(13.0%) | 290(9.8%) | 231(8.1%) |
| Current smoking (%) | 4921(40.5%) | 4321(40.3%) | 2567(52.1%) | 947(32.0%) | 807(28.4%) |
| Congestive heart failure (%) | 261 (2.1%) | 134 (1.2%) | 6 (0.1%) | 35 (1.2%) | 93 (3.3%) |
| Chronic kidney disease (%) | 221 (1.8%) | 219 (2.0%) | 19 (0.4%) | 44 (1.5%) | 156 (5.5%) |
| Chronic lung disease (%) | 241 (2.0%) | 129 (1.2%) | 30 (0.6%) | 36 (1.2%) | 63 (2.2%) |
| Chronic liver disease (%) | 102 (0.8%) | 83 (0.8%) | 37 (0.8%) | 24 (0.8%) | 22 (0.8%) |
| Cancer (%) | 262 (2.2%) | 143 (1.3%) | 39 (0.8%) | 54 (1.8%) | 50 (1.8%) |
| Prior AMI (%) | 336 (2.8%) | 398 (3.7%) | 141 (2.9%) | 116 (3.9%) | 141 (5.0%) |
| Prior CVA (%) | 861 (7.1%) | 635 (5.9%) | 171 (3.5%) | 191 (6.5%) | 273 (9.6%) |
| Prior PCI (%) | 858 (7.1%) | 563 (5.3%) | 223 (4.5%) | 181 (6.1%) | 159 (5.6%) |
| Prior CABG (%) | 80 (0.7%) | 87 (0.8%) | 16 (0.3%) | 34 (1.1%) | 37 (1.3%) |
| Family history of heart disease (%) | 1143 (9.4%) | 697 (6.5%) | 464 (9.4%) | 127 (4.3%) | 106 (3.7%) |
| Past medical history | |||||
| Aspirin (%) | 2101 (17.3%) | 1090(10.2%) | 401 (8.1%) | 340 (11.5%) | 349 (12.3%) |
| Anti-platelet (%) | 821 (6.8%) | 467 (4.4%) | 163 (3.3%) | 133 (4.5%) | 171 (6.0%) |
| Anti-coagulant (%) | 70 (0.6%) | 56 (0.5%) | 22 (0.4%) | 14 (0.5%) | 20 (0.7%) |
| Statin (%) | 1197 (9.9%) | 589 (5.5%) | 226 (4.6%) | 176 (6.0%) | 187 (6.6%) |
| Chest pain (%) | 10257(84.4%) | 7286(67.9%) | 3593(73.0%) | 2013(68.1%) | 1680(59.1%) |
| Dyspnea (%) | 3449(28.4%) | 1763(16.4%) | 468(9.5%) | 431(14.6%) | 864 (30.4%) |
| Killip Class | |||||
| Class I—II (%) | 10687(87.9%) | 9307(86.8%) | 4901(99.6%) | 2816(95.2%) | 1590(55.9%) |
| Class III (%) | 808 (6.6%) | 877 (8.2%) | 22 (0.4%) | 132 (0.4%) | 723 (25.4%) |
| Class IV (%) | 657 (5.4%) | 539 (5.0%) | 0 (0%) | 9 (0.3%) | 530 (18.6%) |
| Systolic blood pressure, mmHg | 128.8 ± 28.1 | 130.0 ± 26.6 | 136.8 ± 24.7 | 128.6 ± 24.7 | 119.7 ± 28.0 |
| Diastolic blood pressure, mmHg | 78.1 ± 16.2 | 79.7 ± 15.8 | 83.8 ± 15.0 | 78.5 ± 14.3 | 73.7 ± 16.7 |
| Heart rate, bpm | 78.9 ± 20.0 | 77.6 ± 18.3 | 73.5 ± 14.3 | 76.7 ± 16.0 | 85.6 ± 23.5 |
| ST segment elevation (%) | 6494(53.4%) | 5841(54.5%) | 2602(52.9%) | 1616(54.6%) | 1623(57.1%) |
| Cardiac arrest (%) | 242 (2.0%) | 216 (2.0%) | 7 (0.1%) | 20 (0.7%) | 189 (6.6%) |
| Glucose, mg/dL | 171.7 ± 81.3 | 170.1 ± 81.3 | 147.1 ± 52.9 | 169.7 ± 76.9 | 210.2 ±106.8 |
| Creatinine, mg/dL | 1.2 ± 1.0 | 1.1 ± 1.0 | 0.9 ± 0.3 | 1.1 ± 0.9 | 1.6 ± 1.6 |
| CK-MB, ng/mL | 121.3 ± 196.7 | 112.8 ±234.9 | 101.7 ±167.8 | 105.3 ±162.0 | 140.1 ±362.0 |
| Troponin I, ng/mL | 38.7 ± 111.1 | 40.9 ±98.0 | 34.6 ±58.4 | 41.0 ± 98.4 | 51.7 ± 141.7 |
| Total cholesterol, mg/dL | 181.7 ± 45.4 | 182.8 ± 44.5 | 192.1 ± 44.0 | 179.4 ± 41.8 | 170.3 ± 44.3 |
| -cholesterol, mg/dL | 114.4 ± 38.6 | 114.5 ± 38.2 | 122.2 ± 39.7 | 110.9 ± 35.9 | 104.7 ± 34.8 |
AMI indicates acute myocardial infarction; CABG, coronary artery bypass graft; CK, creatinine kinase; CVA, cerebrovascular accident; ECG, electrocardiography; LDL, low density lipoprotein; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI ST-elevation myocardial infarction.
Reclassification table.
| Reclassified predicted risk | Subjects reclassified with | ||||||
|---|---|---|---|---|---|---|---|
| Low risk | Intermediate risk group | High risk | Increased risk | Decreased risk | Net correctly reclassified (%) | ||
| 7 | 5 | 5 | 34 (7.2%) | 31 (6.6%) | |||
| 9 | 17 | 24 | |||||
| 0 | 22 | 384 | |||||
| 2580 | 253 | 40 | 573 (5.6%) | 3678 (35.9%) | |||
| 1937 | 1309 | 280 | |||||
| 390 | 1351 | 2110 | |||||
Fig 4Reclassification of Individuals predicted to be at intermediate risk group by additional assessment of DAMI.
DAMI denotes deep-learning-based risk stratification for the mortality of patients with AMI and GRACE denotes global registry of acute coronary event.
Fig 5Kaplan-Meier survival curve stratified by deep-learning model risk score group.